Target intelligence / Profile preview

Cellular autophagy (Autophagy)

Target
Autophagy
Molecular classification
Biological process, Proteolytic system, Intracellular degradation pathway
01

Overview

Cellular autophagy is a fundamental, evolutionary conserved catabolic process through which cells degrade and recycle their own cytoplasm, damaged organelles, and long-lived proteins via the lysosomal machinery. This process is essential for maintaining cellular homeostasis, especially during periods of nutrient deprivation or metabolic stress, by providing an internal source of energy and building blocks. In clinical medicine, autophagy is considered a "double-edged sword"; while it acts as a tumor suppressor by preventing the accumulation of damaged components, it can also promote the survival of established cancer cells under chemotherapy-induced stress. Therapeutic strategies focus on either inducing autophagy to clear protein aggregates in neurodegenerative conditions like Alzheimer’s and Parkinson’s or inhibiting the pathway to sensitize tumors to treatment. Because autophagy is a complex multi-step pathway involving numerous proteins (such as the Atg family and mTOR), targeting it requires precise modulation to avoid disrupting essential physiological functions in healthy tissues.

Other names
MacroautophagyAutophagic pathwaySelf-eatingAutophagic fluxXenophagy
02

Mechanism of action

Drugs typically modulate this process by inhibiting the Mechanistic target of rapamycin (mTOR) to induce autophagy or by neutralizing lysosomal pH to inhibit autophagic flux.

03

Biological functions

Protein degradationOrganelle turnoverCellular homeostasisNutrient recyclingStress responseInnate immunity
04

Disease associations

CancerNeurodegenerative diseaseInflammationInfectionCardiovascular diseaseMetabolic disorder
05

Safety considerations

Dual role in cancer (tumor suppression vs. tumor survival)Systemic toxicity from broad mTOR inhibitionPotential for neurotoxicity if flux is impairedImmune system modulation risks
06

Interacting drugs

Sirolimus (Rapamycin)

7 more in the full profile.

07

Biomarkers

Microtubule-associated protein 1 light chain 3 (LC3-II)Sequestosome-1 (p62/SQSTM1)Beclin-1 levelsAutophagosome accumulation

Beyond the preview

Go deeper on Cellular autophagy (Autophagy).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellular autophagy (Autophagy).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call